Thiel Capital

Pioneering a biologically enhanced future for humanity.

Network Bio operates a clinical and molecular data library focused on facilitating precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, allowing researchers to analyze patterns and correlations. This analysis can lead to the development of new treatments and diagnostic tools, thereby advancing medical research and improving patient outcomes.

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

Rollup is a software company that offers a collaborative platform aimed at enhancing the development and optimization of complex hardware systems. Utilizing model-based systems engineering, the platform integrates engineering analysis, design, and documentation, facilitating seamless communication among teams. This approach allows users to streamline their processes, reducing reliance on costly tools and specialized software, while also minimizing the need for specially-trained engineers. By providing an efficient and economical solution, Rollup supports teams in building advanced hardware models and systems effectively.

Neros Technologies specializes in autonomous drone services aimed at enhancing defense capabilities. The company has developed a technology-based platform that focuses on keeping personnel off the battlefield, addressing vulnerabilities faced by dismounted soldiers in combat situations. By leveraging advanced drone technology, Neros Technologies seeks to provide innovative solutions that empower clients in the defense sector, helping to improve safety and operational effectiveness against armored threats.

Quantum system develops manufactures and sells unmanned aerial systems, which provide aerial intelligence to commercial and governmental clients around the world.

Heading Health is a technology-enabled mental health platform focused on enhancing access to affordable mental health care. The platform provides personalized treatment solutions that utilize evidence-based therapeutics and innovative technologies, including Spravato, transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By offering these services, Heading Health aims to enable patients to experience meaningful improvements in their mental well-being through effective and accessible treatment options.

Generation Prime is a digital healthcare platform focused on women's healthcare services, particularly in vitro fertilization (IVF) treatments. The company aims to address various family planning and medical needs by offering a closed-loop system for IVF and related health services. Through the integration of technology, Generation Prime enables healthcare professionals to deliver these services more efficiently and at a lower cost, enhancing patient care and accessibility.

SPARK Neuro Inc. is a neuroscience company based in New York, founded in 2013. It specializes in market research for the advertising and entertainment industries, utilizing neuroscience tools to enhance audience engagement and storytelling. Additionally, SPARK Neuro focuses on analyzing brain activity to improve clinical care and therapeutic discovery. The company partners with prestigious institutions to develop its patented neural metrics and advanced machine learning algorithms, exemplified by the SPARK Scan, a 10-minute EEG-based evaluation that helps identify early signs of changes in brain health. Through its innovative platform, SPARK Neuro aims to make brain health measurement universally accessible, enabling healthcare professionals to better understand and address neurological and psychiatric conditions.

Ready helps utility providers connect more families to better services at lower cost.

Alloy Therapeutics is a biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The firm specializes in democratizing access to drug discovery through its innovative platforms and services. Its flagship offering, Alloy-Gx, is a suite of immunocompetent transgenic mice designed for optimal in vivo human antibody discovery. This royalty-free platform allows researchers broad and non-exclusive access to essential drug discovery tools, streamlining the process of antibody project development. By providing these resources, Alloy Therapeutics aims to facilitate advancements in antibody research and ultimately enhance the drug discovery landscape.

Vienna is a smart canvas for ideas. It is a place to collect thoughts and everything that comes with photos, videos, code, music, files, and, of course, text. They serve services for creators, students, and teams to build and discover ideas.

Inflection Points provides training in bitcoin and crypto.

Regent is a maritime mobility company focused on developing electric flying machines for coastal transportation. The company specializes in designing and manufacturing seagliders, which are wing-in-ground-effect crafts that operate a few meters above the water's surface. These innovative vehicles combine the high speed of an airplane with the low operating costs of a boat, enabling them to travel at speeds of up to 180 mph (290 km/h) over suitable ranges for regional trips. Regent's seagliders aim to replace traditional ferries and short-haul aircraft on coastal routes, providing fast, safe, and cost-effective transportation solutions that connect coastal cities and islands. By revolutionizing regional transportation, Regent seeks to enhance connectivity among coastal communities while promoting sustainable travel options.

Mynaric AG specializes in laser communication solutions for high data rate and long-distance wireless data transmission between moving objects. Founded in 2009 and headquartered in Gilching, Germany, the company develops a range of products including air-to-ground, air-to-air, and space terminals, as well as optical ground stations. These systems are essential for aerospace communication networks, enabling ultra-high data rates and secure connectivity for applications across terrestrial, airborne, and space environments. Mynaric operates in two primary segments: Air, which includes HAWK terminals, and Space, featuring CONDOR terminals. Its innovative technology supports a variety of applications such as satellite constellations and high-altitude networks, positioning the company at the forefront of the communication equipment sector. Additional locations in Los Angeles and Washington, D.C. expand its operational reach.

Ex-human specializes in developing a digital human platform that provides customizable interactive artificial intelligence characters. These AI characters are designed to facilitate engaging conversations through text, audio, images, and video, catering to diverse industries such as gaming, dating, chatbots, and influencer marketing. By offering hyper-realistic open-domain conversations, Ex-human enables businesses to enhance user engagement and create entertaining experiences for their audiences.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex was launched with IP from Beth Israel Deaconess Medical Center, is resident at LabCentral in Cambridge.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

Voices is a live video streaming platform that allows creators to monetize their work through donations and subscriptions. Voices will assist content creators in making this a "stunning mass phenomenon," as well as "promote the growth of the creative economy's middle class."

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

Ready helps utility providers connect more families to better services at lower cost.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

Advano, operating under NanoStar, Inc., is a New Orleans-based company founded in 2014 that specializes in silicon nanotechnology. The company focuses on the development and manufacturing of functionalized silicon nanoparticles, which serve as advanced anode materials for lithium-ion batteries. By integrating or replacing graphite with silicon, Advano enhances the energy density and longevity of batteries, making them suitable for electric vehicles, consumer electronics, and defense applications. Its innovative solutions aim to address the challenges of traditional battery technologies, providing scalable and cost-effective options that can easily integrate into existing lithium-ion battery infrastructure. Additionally, Advano's products are designed to support the energy transition and strengthen the domestic battery supply chain.

Chemomab Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on discovering innovative treatments for fibrosis-related diseases that have significant unmet medical needs. Chemomab's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of CCL24, a soluble protein that plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently under clinical development, with a particular emphasis on treating orphan diseases such as Primary Sclerosing Cholangitis and Systemic Sclerosis. The company is conducting three Phase 2 clinical trials for CM-101 in various fibrotic indications and anticipates reporting results from these studies in the near future.

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

SPARK Neuro Inc. is a neuroscience company based in New York, founded in 2013. It specializes in market research for the advertising and entertainment industries, utilizing neuroscience tools to enhance audience engagement and storytelling. Additionally, SPARK Neuro focuses on analyzing brain activity to improve clinical care and therapeutic discovery. The company partners with prestigious institutions to develop its patented neural metrics and advanced machine learning algorithms, exemplified by the SPARK Scan, a 10-minute EEG-based evaluation that helps identify early signs of changes in brain health. Through its innovative platform, SPARK Neuro aims to make brain health measurement universally accessible, enabling healthcare professionals to better understand and address neurological and psychiatric conditions.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Terminal Inc. specializes in talent solutions, focusing on the recruitment, onboarding, and management of remote global tech teams. Founded in 2017 and headquartered in San Francisco, California, the company also has offices in Kitchener, Montreal, Vancouver, Canada, and Jailsco, Mexico. Terminal offers a comprehensive suite of services that includes talent acquisition, operational support, and market insights, enabling businesses to scale efficiently. Additionally, the company develops and manages workspaces and provides operational and legal support, encompassing human resources, benefits, payroll, and stock option administration services. Through its expertise, Terminal fosters a connected tech community to support the growth of engineering teams worldwide.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex was launched with IP from Beth Israel Deaconess Medical Center, is resident at LabCentral in Cambridge.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

Legendary Entertainment is a media company that specializes in creating and distributing content for television and digital platforms globally. The company engages in the development, co-production, co-financing, and distribution of motion pictures, often collaborating with other production studios. Legendary Entertainment focuses on producing content that appeals to mainstream audiences, particularly targeting the influential fandom demographic. Its portfolio includes box-office films, television shows, and comic storylines, showcasing a commitment to delivering diverse entertainment options to viewers around the world.